Baseline immune signature score of Tregs × HLA-DR(+)CD4(+) T cells × PD1(+)CD8(+) T cells predicts outcome to immunotherapy in cancer patients

BACKGROUND: The use of immunotherapy (IT) is rapidly increasing across different tumor entities. PD-L1 expression is primarily used for therapy evaluation. The disadvantages of PD-L1 status are spatial and temporal heterogeneity as well as tumor type-dependent variation of predictive value. To optim...

Descripción completa

Detalles Bibliográficos
Autores principales: Mispelbaum, Rebekka, Hattenhauer, Sandra Tessa, Held, Stefanie Andrea Erika, Brossart, Peter, Heine, Annkristin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9742462/
https://www.ncbi.nlm.nih.gov/pubmed/36518753
http://dx.doi.org/10.3389/fimmu.2022.1054161

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9742462/
https://www.ncbi.nlm.nih.gov/pubmed/36518753
http://dx.doi.org/10.3389/fimmu.2022.1054161

Ejemplares similares